Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Coeptis Therapeutics Holdings, Inc., a leading biopharmaceutical company specializing in innovative cell therapy platforms for cancer treatment, has announced that its Director and Vice President of Operations, Dan Yerace, will be participating in a panel discussion at the BioFlorida Conference. The panel, titled “Ambitious Innovation: Emerging Cell and Gene Therapies,” will take place on October 12th at the Sawgrass Marriott Golf Resort & Spa in Ponte Vedra Beach, FL.

Coeptis Therapeutics is dedicated to developing groundbreaking cell therapy solutions that have the potential to revolutionize cancer treatment and improve patient outcomes. The company’s portfolio includes licensed assets from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology. Coeptis is also collaborating with VyGen-Bio and leading medical researchers at the Karolinska Institutet to develop the GEAR™ cell therapy and companion diagnostic platforms.

The panel discussion at the BioFlorida Conference will focus on the ambitious innovations in the field of emerging cell and gene therapies. With Coeptis Therapeutics at the forefront of this cutting-edge research, Dan Yerace’s participation in the panel will provide valuable insights into the company’s groundbreaking work and its potential impact on cancer treatment.

Coeptis Therapeutics’ business model is centered around maximizing the value of its current product portfolio and rights through strategic partnerships, in-license agreements, and out-license agreements. By expanding its product offerings and targeting cancer treatment, the company aims to disrupt conventional treatment paradigms and bring about significant advancements in the field.

For more information about Coeptis Therapeutics and its innovative cell therapy platforms, visit their website at https://coeptistx.com/.